Zolgensma
Novartis shares new data for Zolgensma in children with SMA
March 5, 2024Musculo-skeletal disorder, Novartis, Zolgensma, sma, spinal muscular atrophy
Novartis has announced new data to continue the support of the clinical benefits of Zolgensma (onasmenogene abeparvovec), for the treatment …
Novartis unveils strong Phase 3 efficacy for one-time therapy Zolgensma in paediatric spinal muscular atrophy
October 1, 2020Research and Development Novartis, Zolgensma, spinal muscular atrophy
Novartis has lifted the curtain on new Phase 3 data from an ongoing trial of 33 participants on the efficacy …
Novartis reveals hard-hitting five-year data for its gene therapy Zolgensma in spinal muscular atrophy
March 25, 2020Research and Development Novartis, Zolgensma, gene therapy, pharma, spinal muscular atrophy
Novartis has revealed five-year data on its gene therapy Zolgensma, boasting that the one-time infusion demonstrated “rapid, significant and clinically …
Japan approves Novartis’ Zolgensma for spinal muscular atrophy in patients under two years old
March 19, 2020Sales and Marketing Japan, Novartis, Zolgensma, pharma, spinal muscular atrophy
Novartis has revealed that its gene therapy Zolgensma (onasemnogene abeparvovec) has secured approval from Japan’s Ministry of Health, Labour and …
Novartis plans giveaways of world’s most expensive drug
December 19, 2019Business Services Novartis, Zolgensma, sma
Novartis plans to giveaway 50 doses of the world’s costliest single-dose treatment, Zolgensma, for babies under 2 years old, with …
FDA slams brakes on trial for world’s most expensive drug following safety concerns in children
October 30, 2019Research and Development FDA, Novartis, Zolgensma, pharma
The FDA has temporarily shut down a clinical trial evaluating Zolgensma – the world’s most expensive drug at $3.1 million …
British baby’s death not caused by Zolgensma says Novartis
September 19, 2019Research and Development AveXis, Novartis, Zolgensma, spinal muscular atrophy
Swiss drugmaker Novartis have stated that a British baby’s death this year after getting Novartis’ gene therapy Zolgensma, was not …
Novartis exec pushed out over Zolgensma data scandal denies wrongdoing
August 21, 2019Research and Development AveXis, FDA, Novartis, Zolgensma, data scandal, pharma, sma
Dr Brian Kaspar, the Novartis exec pushed out of AveXis over the Zolgensma data scandal, has said in a statement …
Novartis exec sold off shares before Zolgensma data scandal was revealed
August 19, 2019Sales and Marketing AveXis, Novartis, Shares, Zolgensma, pharma, stock market
An unnamed Novartis executive sold 925,400 Swiss francs (£778,665) worth of shares in the firm just weeks before the FDA …
Top Ten most popular articles on Pharmafile.com this week!
August 16, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Air pollution, CAR-T therapy, HIV, Kymriah, Medicare, Novartis, Yescarta, Zolgensma
Novartis’ faulty data scandal dominated the headlines this week, as the Swiss firm faced fierce backlash over covering up the …
Senate Finance Comittee Chairman, Chuck Grassley calls on Novartis to reveal details of data scandal
August 13, 2019Research and Development AveXis, Chuck Grassley, Novartis, Zolgensma, sfc
Chuck Grassley, Chairman of the Senate Finance Committee, has demanded that Novartis give up details on the faulty data scandal …
Senators call on FDA to use “forceful response” against Novartis over faulty data scandal
August 12, 2019Sales and Marketing AveXis, Bernie Sanders, Elizabeth Warren, FDA, Novartis, Zolgensma
Five senators, including presidential candidates Bernie Sanders and Elizabeth Warren, have condemned Novartis for using “falsified data… to obtain approval …
Novartis hid faulty data from FDA over $2.1 million gene therapy Zolgensma
August 7, 2019Research and Development AveXis, FDA, Novartis, Zolgensma, gene therapy, pharma
Novartis hid faulty data from the FDA until their drug was approved, according to a statement from Dr Peter Marks, …
Novartis’ $2.15m SMA drug Zolgensma becomes most expensive FDA-approved therapy
May 28, 2019Manufacturing and Production AveXis, FDA, Zolgensma, access, drugs, pricing, sma
The FDA has approved Novartis subsidiary AveXis’ $2.15 million gene therapy Zolgensma for children with spinal muscular atrophy (SMA). The …
Novartis reveals promising interim Phase 3 data for gene therapy Zolgensma in spinal muscular atrophy
April 18, 2019Research and Development Novartis, Zolgensma, pharma
Novartis has revealed new interim data from its Phase 3 trial investigating the efficacy of its gene therapy Zolgensma (onasemnogene …
